Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-07-23

FDA Approved: EDARBI — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for EDARBI (azilsartan kamedoxomil) submitted by Azurity Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Edarbi (azilsartan medoxomil)

Snippet

SUPPL AP for EDARBI (AZILSARTAN KAMEDOXOMIL)